Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)

Masaaki Ouchi; Hitoshi Kawamura; Yasuo Urata; Toshiyoshi Fujiwara

doi:10.1007/s10637-008-9169-5

Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)

Masaaki Ouchi, Hitoshi Kawamura, Yasuo Urata, Toshiyoshi Fujiwara

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

We constructed a replication-competent oncolytic adenovirus, OBP-301 (Telomelysin), in which human telomerase reverse transcriptase (hTERT) promoter drives E1 genes. OBP-301 is currently being used in a phase-I clinical trial for various types of tumors. Under such conditions, anti-adenoviral agents should be available for safety use against OBP-301 since any adenoviral viremia could cause severe adverse effects. Cidofovir (CDV) is an acyclic nucleoside phosphonate that has a broad antiviral activity against DNA viruses. Here, we examined the antiviral effects of CDV against OBP-301. The in vitro cytopathic effects of OBP-301 were suppressed by CDV. Moreover, CDV decreased the adenoviral E1A gene copy number after OBP-301 infection. These results suggest that CDV is a potentially useful antiviral agent for OBP-301.

Original language	English
Pages (from-to)	241-245
Number of pages	5
Journal	Investigational New Drugs
Volume	27
Issue number	3
DOIs	https://doi.org/10.1007/s10637-008-9169-5
Publication status	Published - Jun 2009

Keywords

Adenovirus
Cidofovir
Clinical trial
HTERT
Oncolytic virus

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/s10637-008-9169-5

Cite this

@article{bddd8749a8af49b490ec07c9ad95dcdc,

title = "Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)",

abstract = "We constructed a replication-competent oncolytic adenovirus, OBP-301 (Telomelysin), in which human telomerase reverse transcriptase (hTERT) promoter drives E1 genes. OBP-301 is currently being used in a phase-I clinical trial for various types of tumors. Under such conditions, anti-adenoviral agents should be available for safety use against OBP-301 since any adenoviral viremia could cause severe adverse effects. Cidofovir (CDV) is an acyclic nucleoside phosphonate that has a broad antiviral activity against DNA viruses. Here, we examined the antiviral effects of CDV against OBP-301. The in vitro cytopathic effects of OBP-301 were suppressed by CDV. Moreover, CDV decreased the adenoviral E1A gene copy number after OBP-301 infection. These results suggest that CDV is a potentially useful antiviral agent for OBP-301.",

keywords = "Adenovirus, Cidofovir, Clinical trial, HTERT, Oncolytic virus",

author = "Masaaki Ouchi and Hitoshi Kawamura and Yasuo Urata and Toshiyoshi Fujiwara",

year = "2009",

month = jun,

doi = "10.1007/s10637-008-9169-5",

language = "English",

volume = "27",

pages = "241--245",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)

AU - Ouchi, Masaaki

AU - Kawamura, Hitoshi

AU - Urata, Yasuo

AU - Fujiwara, Toshiyoshi

PY - 2009/6

Y1 - 2009/6

N2 - We constructed a replication-competent oncolytic adenovirus, OBP-301 (Telomelysin), in which human telomerase reverse transcriptase (hTERT) promoter drives E1 genes. OBP-301 is currently being used in a phase-I clinical trial for various types of tumors. Under such conditions, anti-adenoviral agents should be available for safety use against OBP-301 since any adenoviral viremia could cause severe adverse effects. Cidofovir (CDV) is an acyclic nucleoside phosphonate that has a broad antiviral activity against DNA viruses. Here, we examined the antiviral effects of CDV against OBP-301. The in vitro cytopathic effects of OBP-301 were suppressed by CDV. Moreover, CDV decreased the adenoviral E1A gene copy number after OBP-301 infection. These results suggest that CDV is a potentially useful antiviral agent for OBP-301.

AB - We constructed a replication-competent oncolytic adenovirus, OBP-301 (Telomelysin), in which human telomerase reverse transcriptase (hTERT) promoter drives E1 genes. OBP-301 is currently being used in a phase-I clinical trial for various types of tumors. Under such conditions, anti-adenoviral agents should be available for safety use against OBP-301 since any adenoviral viremia could cause severe adverse effects. Cidofovir (CDV) is an acyclic nucleoside phosphonate that has a broad antiviral activity against DNA viruses. Here, we examined the antiviral effects of CDV against OBP-301. The in vitro cytopathic effects of OBP-301 were suppressed by CDV. Moreover, CDV decreased the adenoviral E1A gene copy number after OBP-301 infection. These results suggest that CDV is a potentially useful antiviral agent for OBP-301.

KW - Adenovirus

KW - Cidofovir

KW - Clinical trial

KW - HTERT

KW - Oncolytic virus

UR - http://www.scopus.com/inward/record.url?scp=64649089999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64649089999&partnerID=8YFLogxK

U2 - 10.1007/s10637-008-9169-5

DO - 10.1007/s10637-008-9169-5

M3 - Article

C2 - 18754077

AN - SCOPUS:64649089999

SN - 0167-6997

VL - 27

SP - 241

EP - 245

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this